北京诺禾致源科技股份有限公司 董事、监事及高级管理人员薪酬管理制度 北京诺禾致源科技股份有限公司 董事、监事及高级管理人员薪酬管理制度 第一章 总则 第一条 为进一步完善北京诺禾致源科技股份有限公司（以下简称"公司"） 董事、监事与高级管理人员的管理结构，加强监督公司董事、监事及高级管理人 员（以下简称"董监高"）薪酬的管理规范准则，建立科学有效的激励与约束机 制，积极有效地调动公司董事、监事及高级管理人员的工作积极性，提升公司的 经营管理效益，根据《中华人民共和国公司法》（以下简称"《公司法》"）、《上市 公司治理准则》《上海证券交易所科创板股票上市规则》《上海证券交易所科创板 上市公司自律监管指引第 1 号——规范运作》等有关法律法规、规范性文件及 《北京诺禾致源科技股份有限公司章程》（以下简称"《公司章程》"）的有关规定， 制定本薪酬管理制度。 第二条 本制度适用于以下人员： （一）董事（包括独立董事及股东派出董事）； （二）监事（包括股东代表监事和职工代表监事）； （三）高级管理人员（包括总经理、副总经理、财务总监、董事会秘书以及 《公司章程》规定的其他高级管理人员）。 （五）薪酬考核采用科学严谨的方 ...

北京诺禾致源科技股份有限公司 独立董事候选人声明 本人王天儿,已充分了解并同意由提名人北京诺禾致源科技股份有限公司董 事会提名为北京诺禾致源科技股份有限公司(以下简称"该公司")第三届董事 会独立董事候选人。本人公开声明,本人具备独立董事任职资格,保证不存在任 何影响本人担任该公司独立董事独立性的关系,具体声明如下: 一、本人具备上市公司运作的基本知识,熟悉相关法律、行政法规、规章及 其他规范性文件,具有五年以上法律、经济、财务、管理或者其他履行独立董事 职责所必需的工作经验。本人尚未根据《上市公司高级管理人员培训工作指引》 及相关规定取得独立董事资格证书。本人承诺在本次提名后,参加上海证券交易 所举办的最近一期独立董事资格培训并取得独立董事资格证书。 二、本人任职资格符合下列法律、行政法规和部门规章的要求; (一) 《中华人民共和国公司法》关于董事任职资格的规定; (二)《中华人民共和国公务员法》关于公务员兼任职务的规定; (三)中央纪委、中央组织部《关于规范中管干部辞去公职或者退〈离〉体 后担任上市公司、基金管理公司独立董事、独立监事的通知》的规定; (二)直接或向接持有该公司已发行股份 1%以上或者是该 ...

证券代码：688315 证券简称：诺禾致源 公告编号：2023-035 北京诺禾致源科技股份有限公司 第三届监事会第九次会议决议公告 本公司监事会及全体监事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、 监事会会议召开情况 具体内容详见公司同日刊载于上海证券交易所网站（http://www.sse.com.cn） 1 的《公司董事、监事及高级管理人员薪酬管理制度》。 北京诺禾致源科技股份有限公司（以下简称"公司"）第三届监事会第九次 会议（以下简称"本次会议"）于 2023 年 8 月 16 日在公司会议室以现场结合通 讯的方式召开，本次会议通知及相关材料已于 2023 年 8 月 11 日以电子邮件方式 送达公司全体监事。公司监事 3 人，实际出席监事 3 人，会议由监事会主席李兴 园女士召集并主持。本次会议的召集、召开和表决程序符合《中华人民共和国公 司法》等法律法规、规范性文件和《北京诺禾致源科技股份有限公司章程》、《北 京诺禾致源科技股份有限公司监事会议事规则》的有关规定，会议形成的决议合 法、有效。 二、 监事会会议审议情况 经与 ...

证券代码：688315 证券简称：诺禾致源 公告编号：2023-034 重要内容提示： 一、 召开会议的基本情况 （一） 股东大会类型和届次 北京诺禾致源科技股份有限公司 关于召开 2023 年第二次临时股东大会的通知 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 2023 年第二次临时股东大会 召开日期时间：2023 年 9 月 1 日 13 点 30 分 召开地点：北京市朝阳区酒仙桥北路甲 10 号院 301 号楼 101 栋诺禾致源大 厦一楼多功能厅 （五） 网络投票的系统、起止日期和投票时间。 网络投票系统：上海证券交易所股东大会网络投票系统 网络投票起止时间：自 2023 年 9 月 1 日 至 2023 年 9 月 1 日 股东大会召开日期：2023年9月1日 本次股东大会采用的网络投票系统：上海证券交易所股东大会网络投票 系统 （二） 股东大会召集人：董事会 （三） 投票方式：本次股东大会所采用的表决方式是现场投票和网络投票相结 合的方式 （四） 现场会议召开的日期、时间和地点 采用上海证券交易所网络投票系统 ...

北京诺禾致源科技股份有限公司 关于独立董事辞职的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 北京诺禾致源科技股份有限公司（以下简称"公司"）独立董事泮伟江先生 因个人原因于近日向公司董事会递交了辞职报告，申请辞去公司第三届董事会独 立董事职务及董事会下设专门委员会相应职务。辞职后，泮伟江先生不再担任公 司任何职务。泮伟江先生在担任公司独立董事期间勤勉尽责，公司董事会对泮伟 江先生在任职期间为公司所做的各项工作和贡献表示衷心感谢。 证券代码：688315 证券简称：诺禾致源 公告编号：2023-032 北京诺禾致源科技股份有限公司董事会 2023 年 8 月 12 日 根据《中华人民共和国公司法》、《上海证券交易所科创板上市公司自律监 管指引第 1 号——规范运作》以及《公司章程》等相关规定，由于泮伟江先生的 辞职将导致公司独立董事人数低于董事会成员的三分之一，其辞职应当在新任独 立董事补选后生效。在此之前，泮伟江先生仍将按照法律、法规及《公司章程》 的相关规定继续正常履行独立董事职责及董事会专门委员会中相应职务。 ...

Financial Performance - The company reported a significant increase in revenue for the first half of 2023, achieving a total of RMB 1.2 billion, representing a year-on-year growth of 25%[1]. - The company's operating revenue for the reporting period was CNY 929.92 million, an increase of 9.44% compared to the same period last year, primarily driven by growth in revenue from Hong Kong, Macau, Taiwan, and overseas regions, which reached CNY 46.35 million, up 30.79% year-on-year[24]. - The net profit attributable to shareholders was CNY 75.03 million, a 32.34% increase from the previous year, due to higher operating revenue, improved capital efficiency, and increased foreign exchange gains[24]. - Basic and diluted earnings per share were CNY 0.19, reflecting a growth of 35.71% compared to the same period last year, influenced by the increase in net profit attributable to shareholders[24]. - The net cash flow from operating activities was -CNY 4.51 million, an improvement from -CNY 19.08 million in the same period last year, mainly due to increased customer payments[24]. - The company's total assets at the end of the reporting period were CNY 3,113.27 million, a 2.13% increase from the end of the previous year[24]. - The company's net assets attributable to shareholders were CNY 2,038.62 million, up 3.75% from the end of the previous year[24]. - The company achieved a revenue of 929.92 million RMB in the first half of 2023, representing a year-on-year growth of 9.44%[83]. - The net profit attributable to shareholders reached 75.03 million RMB, marking a year-on-year increase of 32.34%[83]. - Research and development investment totaled 49.69 million RMB, accounting for 5.34% of total revenue[83]. Market Outlook and Growth Strategy - The company provided a positive outlook for the second half of 2023, projecting a revenue growth of 20% to 25%[1]. - New product launches are expected to contribute an additional RMB 300 million in revenue by the end of the year[1]. - Market expansion efforts include entering two new international markets, aiming for a 15% increase in market share[1]. - The company has completed a strategic acquisition of a biotech firm for RMB 500 million, enhancing its product portfolio[1]. Research and Development - The company is investing in R&D, with an allocation of RMB 150 million for new technology development in genomics[1]. - Research and development expenses accounted for 5.34% of operating revenue, a decrease of 1.24 percentage points compared to the previous year[24]. - The company has published or been cited in nearly 20,000 SCI articles, with a cumulative impact factor of nearly 120,000, and holds 62 patents related to gene sequencing technology[31]. - The company has developed a comprehensive multi-omics service system, including genomics, transcriptomics, and proteomics, to meet the latest research demands[85]. - The company is actively enhancing its transcriptome and epigenomics sequencing technologies, focusing on applications in tumor diagnosis and precision medicine[49]. Operational Efficiency - The management highlighted a focus on improving operational efficiency, targeting a 10% reduction in costs by the end of the fiscal year[1]. - The company has improved overall operational efficiency by 13.5% through over 80 lean improvement activities across various delivery stages, including sample management and sequencing[42]. - The company has established a fully automated workflow for sample extraction, detection, library preparation, and bioinformatics analysis, improving efficiency in newborn screening[72]. Risk Management - There are no significant risks identified that could impact the company's operations in the near term[1]. - The company is facing risks related to a lack of clinical application qualifications, which could limit its market opportunities if new products do not meet expectations[90]. - The company acknowledges the risk of declining product prices due to intense market competition, which could negatively impact its gross and net profit margins[93]. - The company is dependent on a limited number of suppliers for sequencing instruments and reagents, which poses a risk to its operational stability[94]. Corporate Governance and Compliance - The company has established mechanisms for environmental protection and has not reported any significant environmental pollution incidents[134]. - The company has committed to fulfilling all public commitments made during its initial public offering of A-shares and listing on the Sci-Tech Innovation Board[182]. - The company will ensure that any income obtained from non-compliance will be returned to the company within five days[162]. - The company will comply with regulations regarding the restriction of share transfers as per the relevant laws and stock exchange rules[157]. Global Presence and Client Base - The company serves approximately 7,000 clients across nearly 90 countries and regions, significantly leading domestic competitors in global business coverage[77]. - The company has established laboratories in Tianjin, Shanghai, and Guangzhou, as well as localized operations in Singapore, the USA, and the UK, serving nearly 7,000 clients globally[85]. Product Development and Innovation - The company has developed a high-throughput newborn genetic disease screening product based on the Illumina sequencing platform, capable of screening over 100 genetic diseases, significantly improving detection rates compared to traditional methods[72]. - The company has completed the development of a targeted gene detection kit for lung cancer and colorectal cancer, which has received registration certification for three types of medical devices[71]. - The company has developed a low-frequency mutation detection technology for ctDNA, aimed at improving tumor gene detection sensitivity and specificity[71].

证券代码：688315 证券简称：诺禾致源 公告编号：2023-029 北京诺禾致源科技股份有限公司 关于召开 2023 年半年度业绩说明会的公告 会 议 召 开 地 点 ： 上 海 证 券 交 易 所 上 证 路 演 中 心 （ 网 址 ： http://roadshow.sseinfo.com/） 会议召开方式：上证路演中心网络互动 投资者可于 2023 年 8 月 1 日(星期二)至 8 月 7 日(星期一)16:00 前登录上证 路演中心网站首页点击"提问预征集"栏目或通过公司邮箱ir@novogene.com进行 提问。公司将在说明会上对投资者普遍关注的问题进行回答。 北京诺禾致源科技股份有限公司（以下简称"公司"）已于 2023 年 8 月 1 日 发布公司 2023 年半年度报告，为便于广大投资者更全面深入地了解公司 2023 年 上半年的经营成果、财务状况，公司计划于 2023 年 8 月 8 日上午 11:00-12:00 举 行 2023 年半年度业绩说明会，就投资者关心的问题进行交流。 一、 说明会类型 本次投资者说明会以网络互动形式召开，公司将针对 2023 年半年度的经营 成果及财务 ...

Financial Performance - The annual revenue for the year was reported at $500 million, reflecting a 15% growth compared to the previous year[15]. - The company's operating revenue for 2022 was RMB 1,925.63 million, representing a year-on-year increase of 3.17%, primarily driven by revenue growth in Hong Kong, Macau, Taiwan, and overseas markets, with overseas revenue reaching RMB 807.27 million, up 21.25%[27]. - The net profit attributable to shareholders of the listed company was RMB 177.23 million, a decrease of 21.30% compared to the previous year, mainly due to changes in the fair value of financial assets and increased selling and administrative expenses[28]. - Basic and diluted earnings per share for 2022 were RMB 0.44, down 24.14% year-on-year, primarily due to reduced fair value gains and increased expenses[28]. - The net cash flow from operating activities was RMB 303.95 million, reflecting a 3.57% increase from the previous year[25]. - The company's total net assets attributable to shareholders at the end of 2022 were RMB 1,964.90 million, an increase of 9.65% compared to the end of 2021[25]. - The gross margin for the year improved to 60%, up from 55% in the previous year, due to operational efficiencies[14]. - The company reported a quarterly revenue of RMB 560.81 million in Q4 2022, showing a consistent upward trend throughout the year[30]. - The net profit attributable to shareholders in Q4 2022 was RMB 64.39 million, indicating a strong performance in the last quarter[31]. Research and Development - The company is investing $50 million in R&D for next-generation sequencing technologies, aiming to enhance accuracy and reduce costs by 20%[14]. - Research and development expenses accounted for 6.91% of operating revenue, a decrease of 1.15 percentage points from the previous year[27]. - The company has received 57 patents related to gene sequencing technology and 294 software copyrights, indicating its commitment to innovation[45]. - The company has developed a fully automated bioinformatics reporting machine and an automated library construction system, successfully completing the first generation of development[44]. - The company has established research cooperation with multiple top-tier hospitals for its independently developed pathogen metagenomic high-throughput detection products (mNGS) PD-seq series[84]. - The company has developed a comprehensive single-cell sequencing service capability, having published over 150 related research papers globally by the end of 2022[79]. - The company has achieved significant advancements in de novo sequencing technology, obtaining 4 invention patents and successfully assembling the T2T human genome sequence[72]. Market Expansion and Strategy - The company plans to expand its market presence in Europe, targeting a 30% increase in market share by 2025[16]. - The company aims to create a one-stop automated solution to support the implementation of NGS technology in hospitals[44]. - The company is actively expanding its clinical applications of gene technology, with its gene mutation detection kit being one of the first approved in China for high-throughput sequencing-based tumor gene detection[46]. - The company is focusing on integrating various omics data to provide unified management and analysis services for clients[40]. - The company aims to enhance its global localized service network and operational system by establishing new local laboratories worldwide, building on existing facilities in the US, Singapore, and the UK[165]. Corporate Governance - The board of directors has confirmed the authenticity, accuracy, and completeness of the annual report[4]. - The company has not disclosed any special arrangements for corporate governance[6]. - The company’s governance structure complies with relevant laws and regulations, with no significant discrepancies noted[174]. - The company’s financial status and major asset restructuring are supervised by the supervisory board to protect shareholder rights[175]. - The company’s board secretary is responsible for information disclosure and investor relations, ensuring timely and accurate information dissemination[174]. Risks and Challenges - The company has not reported any significant risks that could materially affect its operations during the reporting period[4]. - The company is facing risks from intense market competition leading to potential price declines in genomic services[103]. - The company is highly dependent on key suppliers like Illumina and Thermo Fisher, which poses a supply risk[104]. - The company plans to diversify its supplier base to mitigate reliance on a few key suppliers[104]. Innovations and Technology - The company has developed a targeted method for absolute quantification of amino acids, enhancing the stability and repeatability of the product[91]. - The company has optimized its RNA sequencing and epigenomics technologies, achieving a valid rate of over 70% in library construction for various species[76]. - The company has made significant breakthroughs in third-generation sequencing technology, achieving industry-leading results in metagenomic sequencing applications[83]. - The company is exploring new technologies such as long-read sequencing and methylation sequencing for clinical applications[84]. Shareholder Returns - The company plans to distribute a cash dividend of RMB 0.047 per share, totaling RMB 18,809,400, which represents 10.61% of the net profit attributable to shareholders[5]. - The company does not plan to issue bonus shares or convert capital reserves into share capital for the 2022 fiscal year[5]. - The company has a three-year dividend return plan for shareholders from 2022 to 2024, which was also approved by the board[191].

单位：元 币种：人民币 (二)非经常性损益项目和金额 2023 年第一季度报告 四、 季度财务报表 2023 年第一季度报告 2023 年起首次执行新会计准则或准则解释等涉及调整首次执行当年年初的财务报表 □适用 √不适用 第一季度财务报表是否经审计 3 / 13 | --- | --- | |-----------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------| | 上述股东关联关系或一致行动的说明 | 北京致源禾谷投资管理中心（有限合伙）和北京诺禾禾谷投资管理中心（有限合伙）的普通合伙人、 执行事务合伙人均为李瑞强。公司未知上述其他股东之间是否有关联关系或一致行动关系。 ...

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 证券代码：688315 证券简称：诺禾致源 公告编号：2023-017 北京诺禾致源科技股份有限公司 关于召开 2022 年度业绩说明会的公告 重要内容提示： 会议召开时间：2023 年 4 月 20 日(星期四)下午 13:00-14:00 会 议 召 开 地 点 ： 上 海 证 券 交 易 所 上 证 路 演 中 心 （ 网 址 ： http://roadshow.sseinfo.com/） 会议召开方式：上证路演中心网络互动 投资者可于 2023 年 4 月 13 日(星期四)至 4 月 19 日(星期三)16:00 前登录上 证路演中心网站首页点击"提问预征集"栏目或通过公司邮箱ir@novogene.com进 行提问。公司将在说明会上对投资者普遍关注的问题进行回答。 北京诺禾致源科技股份有限公司（以下简称"公司"）已于 2023 年 4 月 13 日 发布公司 2022 年年度报告，为便于广大投资者更全面深入地了解公司 2022 年度 经营成果、财务状况，公司计划于 ...